USPTO serial 79368307
BIOSCEPTRE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 18, 2024
- Examiner
- BULLOFF, TOBY ELLEN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BIOSCEPTRE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Timothy J. Kelly
Timothy J. Kelly T.J. KELLY INTELLECTUAL PROPERTY LAW, P.P.O. Box 128Bay Head, NJ 08742UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biopharmaceutical and pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; veterinary preparations, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; veterinary preparations, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; biological preparations for veterinary purposes, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; biological preparations for veterinary purposes, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; cultures of microorganisms for medical and veterinary use; biological preparations for medical purposes, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; biological preparations for medical purposes, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; drugs for medical purposes, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; drugs for medical purposes, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; diagnostic preparations for medical purposes; enzymes for medical purposes; biochemical medicines for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; vaccines; bioengineering pharmaceutical solutions for use in expanding cells for therapeutic use to patients with blood cancers and other diseases; biopharmaceuticals, namely biopharmaceutical products for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; cells and biological preparations, namely, blood, stem cells, adult blood cells, immune cells, immunomodulatory cells, umbilical cord cells, umbilical cord blood, and placental tissue intended for medical and clinical use, including, blood, stem cells, adult blood cells, immune cells, immunomodulatory cells, umbilical cord cells, umbilical cord blood, and placental tissue; bioengineered cells for use in immunotherapies; diagnostic substances and diagnostic preparations for medical purposes; gene and cell therapy and prophylaxis products, namely, therapeutic pharmaceuticals for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; gene and cell therapy prophylaxis vector preparations for therapeutic purposes for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; pharmaceutical preparations and products, namely pharmaceutical preparations and products for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; pharmaceutical preparations in the nature of cell solutions to enable cell expansion for therapeutic purposes; reagents for ex vivo cell processing in particular media suitable for the expansion of cells for therapeutic purposes; cell products for therapeutic purposes, namely stem and progenitor cell, adult cell, immune cell, cell therapy and gene therapy products; cells for medical purposes | ACTIVE | — |
| 042 | Analysis of biological samples; biopharmaceutical and pharmaceutical development and research and evaluation services in the field of cell based therapeutics and gene therapy for the treatment of disease, injuries and disorders; biotechnology laboratory services; medical and scientific laboratory services; scientific, medical and clinical research consultation services and scientific, medical and clinical research and development services, including in the field of hematology, immunology, cancer research, developmental biology and life sciences, biotechnology, medical technology, cell culture, tissue engineering, genetic engineering, regenerative medicine, immunotherapy and immunomodulation; medical and scientific research, namely, conducting pre-clinical and clinical trials for others; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceutical preparations and substances for use in clinical trials; chemical analysis; industrial design; conducting technical project studies in the fields of medicine, biotechnology, therapeutics, pharmaceuticals, biopharmaceuticals, biotherapeutics, radiology, cardiology, oncology, epidemiology, pulmonology, neurology, hematology, endocrinology, otolaryngology, gastroenterology, nephrology, gynecology, obstetrics, urology, orthopedics, ophthalmology, pathology, pediatrics, surgery, medical genetics, medical genomics, dermatology, immunology, and preventive medicine; research and development of new products for others; material testing; biological research; scientific laboratory services; scientific research; bacteriological research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Biosceptre (Aust) Pty Ltd
- Other trademarks owned by Biosceptre (Aust) Pty Ltd
- Other trademarks owned by Biosceptre (Aust) Pty Ltd
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named BIOSCEPTRE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 21, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 4, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 4, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 18, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 18, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 18, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 16, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 2, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 2, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 27, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 27, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 13, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 29, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 28, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 28, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 28, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 28, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 8, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 8, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 8, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 25, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 30, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 30, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 19, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 18, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 18, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 2, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 28, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 27, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |